About Globus Medical (NYSE:GMED)
Globus Medical, Inc. (Globus) is a medical device company focused on the design, development and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. The Company is focused on implants that promote healing in patients with spine disorders. The Company's products fall into one of two categories: Innovative Fusion or Disruptive Technologies. The Company sells its products through exclusive sales force in the United States, as well as within North, Central & South America, Europe, Asia, Africa and Australia. The sales force consists of direct sales representatives and distributor sales representatives employed by exclusive independent distributors.
Industry, Sector and Symbol
Industry MED PRODS
Sub-IndustryHealth Care Equipment
Trailing P/E Ratio46.1731470286094
Forward P/E Ratio33.95
Sales & Book Value
Annual Sales$635.98 million
Price / Sales7.72
Cash Flow$1.77 per share
Price / Cash28.76
Book Value$10.04 per share
Price / Book5.07
Net Income$107.34 million
Return on Equity13.93%
Return on Assets12.59%
Globus Medical (NYSE:GMED) Frequently Asked Questions
What is Globus Medical's stock symbol?
Globus Medical trades on the New York Stock Exchange (NYSE) under the ticker symbol "GMED."
How were Globus Medical's earnings last quarter?
Globus Medical Inc (NYSE:GMED) released its earnings results on Wednesday, February, 21st. The medical device company reported $0.38 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.35 by $0.03. The medical device company earned $176.03 million during the quarter, compared to analyst estimates of $175.50 million. Globus Medical had a return on equity of 13.93% and a net margin of 16.88%. The business's quarterly revenue was up 16.1% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.31 earnings per share. View Globus Medical's Earnings History.
When will Globus Medical make its next earnings announcement?
What guidance has Globus Medical issued on next quarter's earnings?
Globus Medical issued an update on its FY18 earnings guidance on Wednesday, February, 21st. The company provided EPS guidance of approx $1.50 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.50. The company issued revenue guidance of approx $690 million, compared to the consensus revenue estimate of $690.85 million.
Where is Globus Medical's stock going? Where will Globus Medical's stock price be in 2018?
11 equities research analysts have issued 1 year price targets for Globus Medical's shares. Their predictions range from $36.00 to $53.00. On average, they expect Globus Medical's stock price to reach $48.83 in the next twelve months. View Analyst Ratings for Globus Medical.
What are Wall Street analysts saying about Globus Medical stock?
Here are some recent quotes from research analysts about Globus Medical stock:
- 1. According to Zacks Investment Research, "Globus Medical, Inc. is a medical device company focused on the design, development and commercialization of products that promote healing in patients with spine disorders. The Company's products fall into one of two categories: innovative fusion or disruptive technologies. Its innovative fusion products address a broad range of spinal fusion surgical procedures. Its disruptive technology products include minimally invasive surgical, motion preservation and advanced biomaterials technologies. Globus Medical, Inc. is based in Audubon, Pennsylvania. " (3/13/2018)
- 2. Canaccord Genuity analysts commented, "We recently had the opportunity to host a fireside chat with Globus, as well as visit the company’s booth during the AAOS conference and came away incrementally more confident in the growth opportunities ahead of the company. Specifically, early feedback and success with the ExcelsiusGPS system reinforce our view that the robotic platform can provide a tailwind to an improving core US spine business. In trauma, we were encouraged by the early excitement around the initial product launches – including 6 recently cleared systems to complement the 5 launched at OTA back in October – which we expect to develop into a growth driver in 2019 and beyond. Net, net, while the valuation certainly reflects continued execution in 2018, we are increasingly optimistic that the improving fundamentals in the core US spine business, early success in robotics, and OUS momentum are capable of delivering continued upside to current guidance – thus supporting continued share appreciation." (3/12/2018)
- 3. Needham & Company LLC analysts commented, "GMED’s 4Q17 revenue was consistent with its 1/9/18 preannouncement and its EPS beat consensus. Management reiterated 2018 revenue guidance of $690M and adjusted EPS guidance of $1.50. We estimate that the Emerging Technology segment drove much of the upside given the incremental revenue and negligible EPS drag. Gross margin was up 250 bps Y/Y and operating margin was up 60 bps Y/Y. We maintain our Hold rating since we believe that GMED’s valuation appropriately reflects its Emerging Technologies business’ potential." (2/22/2018)
Who are some of Globus Medical's key competitors?
Some companies that are related to Globus Medical include William Demant Hol (WILYY), Steris (STE), Bio-Rad Laboratories (BIO), West Pharmaceutical Services (WST), Hill-Rom (HRC), DexCom (DXCM), Gn Store Nord (GNNDY), ICU Medical (ICUI), Insulet (PODD), Agios Pharmaceuticals (AGIO), Cantel Medical (CMD), Sartorius (SARTF), Masimo (MASI), Hutchison China MediTech (HCM), Penumbra (PEN), LivaNova (LIVN), Aurora Cannabis (ACBFF) and ELEKTA (EKTAY).
Who are Globus Medical's key executives?
Globus Medical's management team includes the folowing people:
- David C. Paul, Executive Chairman of the Board (Age 50)
- Anthony L. Williams, President (Age 46)
- David M. Demski, Chief Executive Officer, Director (Age 59)
- Daniel T. Scavilla, Chief Financial Officer, Senior Vice President (Age 52)
- Andrew Brett Murphy, Group President, Commercial Operations (Age 52)
- Kurt C. Wheeler, Lead Independent Director (Age 64)
- David D. Davidar, Director (Age 51)
- Daniel T. Lemaitre, Independent Director (Age 63)
- Robert W. Liptak CPA, Independent Director (Age 53)
- Ann D. Rhoads, Independent Director (Age 51)
Has Globus Medical been receiving favorable news coverage?
Media stories about GMED stock have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm ranks the sentiment of media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Globus Medical earned a coverage optimism score of 0.22 on Accern's scale. They also gave news articles about the medical device company an impact score of 46.78 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near term.
Who are Globus Medical's major shareholders?
Globus Medical's stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.09%), Bank of New York Mellon Corp (1.93%), Standard Life Aberdeen plc (1.79%), GW&K Investment Management LLC (1.34%), NWQ Investment Management Company LLC (1.29%) and AXA (0.96%). Company insiders that own Globus Medical stock include A Brett Murphy, Anthony L Williams, David D Davidar and Steven Payne. View Institutional Ownership Trends for Globus Medical.
Which major investors are selling Globus Medical stock?
GMED stock was sold by a variety of institutional investors in the last quarter, including Deutsche Bank AG, Nuance Investments LLC, The Manufacturers Life Insurance Company , Bank of New York Mellon Corp, Glenmede Trust Co. NA, Standard Life Aberdeen plc, Renaissance Technologies LLC and Rice Hall James & Associates LLC. Company insiders that have sold Globus Medical company stock in the last year include A Brett Murphy, Anthony L Williams, David D Davidar and Steven Payne. View Insider Buying and Selling for Globus Medical.
Which major investors are buying Globus Medical stock?
GMED stock was purchased by a variety of institutional investors in the last quarter, including NWQ Investment Management Company LLC, Pembroke Management LTD, Redmile Group LLC, Guggenheim Capital LLC, APG Asset Management N.V., AXA, BlackRock Inc. and Perceptive Advisors LLC. View Insider Buying and Selling for Globus Medical.
How do I buy shares of Globus Medical?
Shares of GMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Globus Medical's stock price today?
One share of GMED stock can currently be purchased for approximately $50.93.
How big of a company is Globus Medical?
Globus Medical has a market capitalization of $4.99 billion and generates $635.98 million in revenue each year. The medical device company earns $107.34 million in net income (profit) each year or $1.10 on an earnings per share basis. Globus Medical employs 1,500 workers across the globe.
How can I contact Globus Medical?
Globus Medical's mailing address is 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA, 19403. The medical device company can be reached via phone at 610-930-1800 or via email at [email protected]
MarketBeat Community Rating for Globus Medical (GMED)MarketBeat's community ratings are surveys of what our community members think about Globus Medical and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Globus Medical (NYSE:GMED) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Buy||Buy||Buy||Hold|
|Consensus Rating Score: ||2.55||2.58||2.50||2.36|
|Ratings Breakdown: ||1 Sell Rating(s)|
3 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
|1 Sell Rating(s)|
3 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
|1 Sell Rating(s)|
4 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
|1 Sell Rating(s)|
5 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
|Consensus Price Target: ||$48.83||$40.57||$36.83||$30.57|
|Price Target Upside: ||4.12% downside||9.56% downside||2.09% downside||1.84% upside|
Globus Medical (NYSE:GMED) Consensus Price Target History
Globus Medical (NYSE:GMED) Analyst Ratings History
(Data available from 3/20/2016 forward)
Globus Medical (NYSE:GMED) Earnings History and Estimates Chart
Globus Medical (NYSE GMED) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|2/21/2018||Q4 2017||$0.35||$0.38||$175.50 million||$176.03 million||View||Listen|
|11/8/2017||Q3 2017||$0.30||$0.30||$150.73 million||$151.74 million||View||N/A|
|8/2/2017||Q2 2017||$0.30||$0.32||$150.94 million||$152.39 million||View||Listen|
|5/3/2017||Q1 2017||$0.31||$0.32||$155.81 million||View||Listen|
|2/27/2017||Q416||$0.33||$0.31||$149.30 million||$151.59 million||View||Listen|
|11/8/2016||Q3||$0.28||$0.29||$139.25 million||$135.70 million||View||Listen|
|7/26/2016||Q2||$0.29||$0.29||$141.78 million||$137.49 million||View||Listen|
|5/3/2016||Q1||$0.28||$0.29||$140.30 million||$139.30 million||View||Listen|
|2/24/2016||Q4||$0.30||$0.32||$141.20 million||$142.60 million||View||Listen|
|11/3/2015||Q3||$0.25||$0.28||$127.46 million||$137.00 million||View||Listen|
|7/30/2015||Q215||$0.25||$0.25||$126.89 million||$133.60 million||View||Listen|
|5/5/2015||Q115||$0.24||$0.26||$122.30 million||$131.60 million||View||Listen|
|2/25/2015||Q414||$0.25||$0.30||$127.77 million||$128.80 million||View||Listen|
|10/30/2014||Q314||$0.21||$0.24||$113.10 million||$117.80 million||View||Listen|
|8/5/2014||Q214||$0.23||$0.23||$119.83 million||$113.60 million||View||Listen|
|4/29/2014||Q114||$0.22||$0.24||$113.59 million||$114.20 million||View||Listen|
|2/26/2014||Q413||$0.22||$0.25||$114.96 million||$115.20 million||View||Listen|
|10/30/2013||Q313||$0.19||$0.22||$106.00 million||$107.19 million||View||Listen|
|8/1/2013||Q2 2013||$0.20||$0.21||$107.46 million||$107.00 million||View||Listen|
|5/2/2013||Q1 2013||$0.20||$0.21||$103.14 million||$105.00 million||View||Listen|
|2/27/2013||Q4 2012||$0.19||$0.22||$99.13 million||$100.50 million||View||Listen|
|11/1/2012||Q312||$0.19||$0.18||$95.32 million||$94.76 million||View||N/A|
Globus Medical (NYSE:GMED) Earnings Estimates
2018 EPS Consensus Estimate: $1.52
2019 EPS Consensus Estimate: $1.68
(Earnings estimates data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Globus Medical (NYSE:GMED)
No dividend announcements for this company have been tracked by MarketBeat.com
Globus Medical (NYSE GMED) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 28.21%
Institutional Ownership Percentage: 65.88%
Globus Medical (NYSE GMED) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|12/15/2017||Steven Payne||CAO||Sell||3,076||$39.30||$120,886.80||23,847|| |
|12/13/2017||Anthony L Williams||President||Sell||15,000||$38.30||$574,500.00||15,000|| |
|12/4/2017||David D Davidar||Director||Sell||55,383||$40.66||$2,251,872.78||752,236|| |
|11/9/2017||A Brett Murphy||Insider||Sell||51,449||$35.00||$1,800,715.00||49,768|| |
|9/6/2017||A Brett Murphy||Insider||Sell||15,000||$29.99||$449,850.00||101,217|| |
|6/5/2017||Anthony L Williams||President||Sell||16,153||$31.94||$515,926.82||16,153|| |
|8/5/2016||A Brett Murphy||Insider||Sell||107,692||$23.37||$2,516,762.04||190,917|| |
|1/6/2016||Robert Liptak||Director||Sell||15,300||$27.50||$420,750.00||26,159|| |
|1/4/2016||Kurt Wheeler||Director||Sell||255||$27.50||$7,012.50||44,319|| |
|5/28/2015||Steven Payne||CAO||Sell||3,076||$25.92||$79,729.92|| |
|3/19/2015||David C Paul||CEO||Sell||1,922,000||$25.00||$48,050,000.00|| |
|1/15/2014||David Demski||COO||Sell||96,813||$20.51||$1,985,634.63||381,365|| |
|12/31/2013||David Demski||COO||Sell||3,187||$20.25||$64,536.75||478,178|| |
|12/20/2013||David Demski||COO||Sell||50,000||$19.75||$987,500.00||481,365|| |
|12/6/2013||Robert Liptak||Director||Sell||25,000||$19.36||$484,000.00||26,159|| |
|12/3/2013||David Davidar||VP||Sell||75,000||$19.25||$1,443,750.00||897,275|| |
|11/27/2013||David Demski||COO||Sell||37,323||$19.25||$718,467.75||531,365|| |
|11/1/2013||David M Demski||COO||Sell||112,677||$18.59||$2,094,665.43|| |
|8/23/2013||David Davidar||VP||Sell||7,278||$18.20||$132,459.60||997,499|| |
|8/22/2013||David Demski||COO||Sell||44,154||$17.95||$792,564.30||681,365|| |
|7/5/2013||David D Davidar||VP||Sell||10,000||$17.15||$171,500.00|| |
|7/1/2013||David D Davidar||VP||Sell||20,000||$16.56||$331,200.00|| |
|6/26/2013||David D Davidar||VP||Sell||150,000||$16.71||$2,506,500.00|| |
|8/8/2012||David C Paul||CEO||Sell||3,039,385||$11.16||$33,919,536.60|| |
|8/8/2012||David D Davidar||VP||Sell||166,885||$11.16||$1,862,436.60|| |
|8/8/2012||David M Demski||COO||Sell||98,957||$11.16||$1,104,360.12|| |
|8/8/2012||Kurt Wheeler||Director||Sell||804,232||$11.16||$8,975,229.12|| |
|8/8/2012||Steven Payne||CAO||Sell||2,305||$11.16||$25,723.80|| |
Globus Medical (NYSE GMED) News Headlines
Globus Medical (NYSE:GMED) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Globus Medical (NYSE:GMED) Income Statement, Balance Sheet and Cash Flow Statement
Globus Medical (NYSE GMED) Stock Chart for Tuesday, March, 20, 2018